Leading-edge AI solution for 2D mammography enhances cancer detection performance for clinicians, with improved sensitivity, specificity, and processing times over previous versions

Latest generation of ProFound AI Risk, now available for digital breast tomosynthesis, provides an accurate, short-term breast cancer risk estimation for women, based only on a screening mammogram

iCAD will unveil the latest generation of ProFound AI® f... Continue reading

Leading-edge AI solution for 2D mammography enhances cancer detection performance for clinicians, with improved sensitivity, specificity, and processing times over previous versions

Latest generation of ProFound AI Risk, now available for digital breast tomosynthesis, provides an accurate, short-term breast cancer risk estimation for women, based only on a screening mammogram

NASHUA, N.H. and PARIS – October 7, 2021 - iCAD, Inc... Continue reading

Dense breasts can make it challenging to detect breast cancer during annual screenings, as overlapping tissue can hide or mimic breast cancer, even with digital breast tomosynthesis (DBT) exams. Breast density assessment has traditionally been determined by the radiologist’s visual assessment, but studies show that these can vary, and clinicians may even disagree with their own assessment year to year.[1] This can be confusing for patients, lead to unnecessary additional imaging, and increase patient and facility costs.

Continue reading

iCAD, Inc. recently launched ProFound AI® Risk for digital breast tomosynthesis (DBT), or 3D mammography, the world’s first commercially available clinical decision support tool that provides an accurate[1],[2] short-term breast cancer risk estimation that is truly personalized for each woman, based only on a 2D or 3D mammogram. The latest version of this software offers improved accuracy and enhanced functionality compared to previous versions.

“ProFound AI Risk has... Continue reading

Latest generation of ProFound AI Risk offers greater accuracy and ethnically inclusive precision screening

Technology provides critical, risk-adaptive solutions for clinicians facing complex screening challenges presented by the COVID-19 pandemic

NASHUA, N.H. – September 29, 2021 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the launch of ProFound AI® Risk for digital breast tomosynthesis... Continue reading

ImageCare Centers recently announced it will adopt ProFound AI® for Digital Breast Tomosynthesis (DBT) throughout all of ImageCare’s mammography centers this October as part of its “PINK Better Mammo” service. ProFound AI® was the first artificial intelligence (AI) software for DBT, or 3D mammography, to be FDA cleared; the software is clinically proven to improve accuracy and efficiency for radiologists reading mammography.[i]

Continue reading

Leading experts to discuss novel AI technology helping them overcome pandemic-related challenges including substantial mammography backlog

NASHUA, N.H. – September 9, 2021 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will host an educational roundtable event to help clinicians and their facilities recover from the impact of the COVID-19 pandemic. Titled “Pandemic Re... Continue reading

Patients treated with Xoft Brain IORT lived for a range of 4 to 54 months after treatment without recurrence, whereas patients in the control group had a recurrence within 2 to 10 months and lived for 2 to 22.5 months after treatment

NASHUA, N.H. – August 31, 2021 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and... Continue reading

NASHUA, N.H., Aug. 05, 2021 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the three and six months ended June 30, 2021.

Revenues for the three-mont... Continue reading

NASHUA, N.H., July 22, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the second quarter and six-months ended June 30, 2021, after the market close, and host a conference call at 4:30pm Eastern Time on Thursday, August 5.

Thursday, August 5th @ 4:30pm ET

Domestic:

888-254-3590

Continue reading

Rabin Medical Center (RMC), one of the most prominent and largest medical facilities in Israel, recently initiated a clinical evaluation involving ProFound AI® for Digital Breast Tomosynthesis (DBT) at the Radiology Department at the Clalit Rabin Medical Center. Owned and operated by Clalit Health Services, RMC is Israel's largest health maintenance organization, with a capacity of 1,300 beds.

“The workload for radiologists had increased significantly at our facility. With an influx of tomosynthesis images to read through each d... Continue reading

iCAD’s third generation artificial intelligence solution for 3D mammography offers considerable improvement in algorithm specificity performance and faster processing compared to previous generations

NASHUA, N.H. – June 14, 2021 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that ProFound AI® Version 3.0 for Digital Breast Tomosynthesis (DBT) received CE Mark approval.

Continue reading

Agreement will expand access to ProFound AI and ProFound AI Risk to more facilities and imaging centers worldwide

NASHUA, N.H. – June 8th, 2021 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it has signed a worldwide distribution agreement with Sectra, an international medical imaging IT and cybersecurity company. Through this agreement, Pr... Continue reading

NASHUA, N.H., May 17, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Michael Klein, iCAD’s Chairman and Chief Executive Officer, will be participating at the following three virtual investor conferences in May and June:

Company sees positive momentum as research contributes to growing body of evidence supporting Xoft intraoperative radiotherapy (IORT) technology for brain cancer

NASHUA, N.H. – May 17, 2021 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced a virtual roundtable discussion will feature leading experts on brain cancer from around the globe sharing clinical updates on how intraoperative radiation therapy (IORT) with the Xo... Continue reading

First Quarter Revenues of .6 Million Represented 32% Year-Over-Year Growth Driven by 28% Growth in Detection Revenue and 41% Growth in Therapy Revenue

ProFound AI ® Product Revenue Increased 34% in the First Quarter of 2021 as Compared to 2020 First Quarter with Continued Adoption of ProFound AI ® Risk Assessment

New research supporting the clinical value of ProFound AI® for Digital Breast Tomosynthesis (DBT) was recently presented at the Society of Breast Imaging (SBI) Symposium, April 9-11, and at the National Consortium of Breast Centers (NCBC) Annual Interdisciplinary Breast Center Conference (NCoBC), April 16-19. Both studies demonstrate ProFound AI helps radiologists identify normal mammograms, as well as those with increased likelihood of malignancy, with greater precision.

At the SBI Symposium, Emily Conant, MD, Profess... Continue reading

NASHUA, N.H., April 20, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the first quarter ended March 31, 2021, after the market close, and host a conference call at 4:30pm Eastern Time on Wednesday, April 28.

Wednesday April 28th @ 4:30pm ET

Domestic:

877-407-0784

Inter... Continue reading

Studies presented at two leading breast imaging conferences demonstrate ProFound AI

helps radiologists identify normal mammograms and those with increased likelihood of malignancy with precision

NASHUA, N.H. – April 19, 2021 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that new research supporting the clinical value of ProFound AI® for Digital Breast Tomosynthesis (D... Continue reading

Company expects preliminary estimated revenues to exceed .1 million

Successor CFO search underway

NASHUA, N.H., April 05, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, reported select preliminary, unaudited financial results for the first quarter of 2021. Based on preliminary, unaudited financial information, the Company expects total revenue for the first quarter of 2021 to... Continue reading